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Abstract
Background: Flavokawain B (FKB) has been identified from kava root extracts as a potent apoptosis inducer for
inhibiting the growth of various cancer cell lines, including prostate cancer. However, the molecular targets of FKB
in prostate cancer cells remain unknown.
Methods: An in vitro NEDD8 Initiation Conjugation Assay was used to evaluate the neddylation inhibitory activity
of FKB. Molecular docking and a cellular thermal shift assay were performed to assess the direct interaction
between FKB and the NEDD8 activating enzyme (NAE) complex. Protein neddylation, ubiqutination, stability and
expression in cells were assessed with immunoprecipitation and Western blotting methods using specific
antibodies. Deletion and site specific mutants and siRNAs were used to evaluate deep mechanisms by which FKB
induces Skp2 degradation. Cell growth inhibition and apoptosis induction were measured by MTT, ELISA and
Western blotting methods.
Results: FKB inhibits NEDD8 conjugations to both Cullin1 and Ubc12 in prostate cancer cell lines and Ubc12
neddylation in an in vitro assay. Molecular docking study and a cellular thermal shift assay reveal that FKB interacts
with the regulatory subunit (i.e. APP-BP1) of the NAE. In addition, FKB causes Skp2 degradation in an ubiquitin and
proteasome dependent manner. Overexpression of dominant-negative cullin1 (1–452), K720R mutant (the
neddylation site) Cullin1 or the F-box deleted Skp2 that losses its binding to the Skp1/Cullin1 complex causes the
resistance to FKB-induced Skp2 degradation, whereas siRNA knock-down of Cdh1, a known E3 ligase of Skp2 for
targeted degradation, didn’t attenuate the effect of FKB on Skp2 degradation. These results suggest that
degradation of Skp2 by FKB is involved in a functional Cullin1. Furthermore, proteasome inhibitors Bortezomib and
MG132 transcriptionally down-regulate the expression of Skp2, and their combinations with FKB result in enhanced
inhibitory effects on the growth of prostate cancer cell lines via synergistic down-regulation of Skp2 and up-
regulation of p27/Kip1 and p21/WAF1 protein expression. FKB also selectively inhibits the growth of RB deficient
cells with high expression of Skp2.
Conclusion: These findings provide a rationale for further investigating combination of FKB and Bortezomib for
treatment of RB deficient, castration-resistant prostate cancer.
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Background
Targeted and combined cancer treatments have signifi-
cantly increased in demand as the side effects and resistant
mechanisms of common therapies have been researched in
greater detail. Neural Precursor Cell Expressed, Develop-
mentally Down-Regulated 8 (NEDD8), an ubiquitin-like
protein, plays an important role in the modification of
Cullin-1 to turn on the Skp1-Cullin-F box protein (SCF)
complex for regulation of the stability of its target proteins
[1]. The neddylation of Cullin1 occurs via a conjugation
cascade-the neddylation pathway, which is initiated by an
E1 (i.e. NEDD8 activating enzyme, NAE) enzyme consisting
of Amyloid Precursor Protein-binding Protein1 (APP-BP1)
and Ubiquitin-Like Modifier Activating Enzyme 3 (UBA3)
proteins. Activated E1 then transfers NEDD8 to its E2 en-
zyme NEDD8-conjugating enzyme 2M (UBE2M), also
called Ubc12, which causes covalent modulation of Cullin
proteins with NEDD8 for activation of Cullin-RING ubiqui-
tin ligases. Many components of the neddylation pathway,
such as NEDD8, NAE and DCN1, have been reported to
be over-expressed in several cancers [2–4]. In addition, high
levels of NEDD8 mRNA were related to resistance to Bor-
tezomib in multiple myeloma patients [5]. Therefore, the
neddylation pathway could be targeted for development of
novel cancer therapies. Indeed, a small molecule inhibitor
of NAE, MLN4924 (a first-in-class inhibitor of NAE also
named as pevonedistat), has been developed and currently
in multiple phase I/II clinical trials for patients with ad-
vanced solid tumors or hematological tumors [6–10]. How-
ever, results from initial trials suggested that MLN4924 as a
single agent has limited anti-tumor efficacy and is dose lim-
iting because of toxicities. Therefore, there is a need for de-
velopment of more efficient or less toxic NAE inhibitors or
novel combination therapies.
Natural products have long been a rich resource for
identifying novel anti-cancer agents with relatively few
side effects. Flavokawain B (FKB) is a naturally occurring
chalone identified in the Kava plant. FKB has been shown
potent anti-tumor activities in xenograft models of a var-
iety of cancers, including in human gastric carcinoma,
breast and prostate cancers in nude mice [11–17]. We
have demonstrated that FKB selectively inhibited the
growth of androgen receptor negative, castration resistant
prostate cancer cell lines with minimal effects on the
growth of normal prostate epithelial and stroma cells [13].
We and other researchers have observed that the cancer
specific cytotoxicity of FKB is associated with the gener-
ation of intracellular reactive oxygen species and
up-regulation of death receptor-5 and Bim expression,
which leads to induction of G2M arrest and apoptosis [13,
15, 18]. However, the molecular targets of FKB in cancer
cells remain unclear. In this study, we have shown that
FKB inhibits NEDD8 conjugations to both Cullin1 and
Ubc12 in prostate cancer cell lines and Ubc12
NEDDylation in an in vitro assay. Molecular docking
study and a cellular thermal shift assay (CETSA) has fur-
ther indicated that FKB directly interacts with the regula-
tory subunit (i.e. APP-BP1) of the NAE. These results
together suggest that FKB is a novel NAE inhibitor.
The neddylation status of the SCF complex is essential for
its function on degradation of both its substrate and itself
[19]. Moreover, individual components of the SCF complex,
including Cullin1, S-phase kinase associated protein 2
(Skp2), copper metabolism domain containing 1 (Commd1),
and cyclin-dependent kinases regulatory subunit 1(Cks1b)
have been linked to Bortezomib resistance in multiple mye-
loma [20]. Here, we have observed that FKB induces a
proteasome-dependent and ubiquitin-mediated degradation
of Skp2 and that the effect of FKB on Skp2 degradation relies
on a functional Cullin1. We have further shown that FKB
markedly enhances the growth inhibitory and apoptotic ef-
fect of proteasome inhibitors MG132 and Bortezomib via
down-regulation of Skp2 and upregulation of p27/Kip1 and
p21/WAF1 protein expression. In addition, FKB preferen-
tially inhibits the growth of RB deficient cells compared to
RB wild-type cells. Our study suggests that FKB and Borte-
zomib combination deserves further investigation for treat-
ment of RB deficient late stage prostate cancer.
Materials and methods
Cell culture
The prostate cancer cell lines LNCaP and PC3 were ob-
tained from American Type Culture Collection (ATCC,
Manassas, VA), while C4-2B prostate cancer cell lines
were purchased from Urocor Inc. (Oklahoma City, OK).
These cells were characterized and authenticated by
ATCC or Urocor Inc. In addition, all cell lines were tested
for known species of mycoplasma contamination using a
kit from LONZA Inc. (Walkersville, MD). These prostate
cancer cells were cultured in RPMI-1640 media (Fisher
Scientific) supplemented with 10% fetal bovine serum
(FBS), 1% L-Glutamine, and 1% penicillin-streptomycin as
described previously in our publication [12, 13]. RB +/+
and RB −/− mouse embryonic fibroblasts (MEFs) and
mouse prostate epithelial cells (MPECs) were obtained
from Dr. Wen-Hwa Lee at the University of California, Ir-
vine and from Dr. Scott D Cramer at Wake Forest Univer-
sity School of Medicine, respectively. These cells were
grown in Dulbecco’s modified Eagle’s media (DMEM) that
has supplements of 10% FBS, 1% L-Glutamine, and 1%
Penicillin-Streptomycin. All cell lines used in this study at
passage 15–20 were used for all experiments.
Compounds, antibodies, and reagents
FKB with 99% purity was isolated from kava extracts by LKT
Laboratories, Inc. (St. Paul, MN). Bortezomib, MG-132 and
MLN4924 were obtained from Cayman Chemical Inc. (Ann
Arbor, MI). Antibodies against Ubc12, ubiquitin, and
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β-tubulin were from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). Anti-Skp2 antibodies were purchased from Invi-
trogen (Grand Island, NY). Anti-Myc-tag and Anti-cleaved--
PARP antibodies were from Cell Signaling (Boston, MA).
Anti-Cullin-1 and anti-NEDD8 antibodies were from Abcam
(Cambridge, MA). Anti-p27/Kip1 and p21/WAF1 antibodies
were from BD Biosciences (Billerica, MA). 3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) was purchased from Sigma. The Reverse Transcrip-
tion System kit and was from Promega (Mandison, WI). A
quantitative reverse transcription polymerase chain reaction
(RT-PCR) kit was from Bio-Rad (Hercules, CA). Ubiquityla-
tion Assay Kit and 20S Proteasome Assay Kit were from
Cayman and Abcam, respectively.
MTT assay
Cells (2 × 104 cells/well) were grown in 24-well culture
dishes for 24 h, and then treated as indicated in the fig-
ures. Cells were then incubated for another 48 h before
adding 1mg/mL MTT in 20% PBS and 80% culture
medium (v/v) for 2 h. The absorbance was read at 570 nm,
and the dose-response curves for reduction of cell viability
were generated as percentage ratios of vehicle-treated
controls.
Western blot analysis
Cellular protein lysates (20-100μg) were denatured in 2X
loading buffer at 100 °C prior to adding into 8–16%
SDS-PAGE. For non-denatured Western blotting analysis,
non-reducing loading buffer were mixed with protein ly-
sates prior to resolving it in non-denaturing gel (Biorad,
CA). Proteins were transferred to nitrocellulose mem-
branes, probed with indicated antibodies, and visualized by
an enhanced chemiluminescence detection system. The
western blotting bands were semi-quantified using Image J
and adjusted for loading controls, β-actin or tubulin.
Plasmid and siRNA transfection
Plasmids of PcDNA-Skp2/myc and pGL2-Skp2 promo
ter-luciferases (Skp2-Luc) were from Addgene No.
19947 and No. 81119, respectively [21]. PcDNA-Skp2/
myc and control vector PCDNA were transfected into
PC3 cells with Fugene 6 from Roche (Indianapolis, IN),
and stable clones were screened for positive expression
of Skp2 and mixed positive clones used in the experi-
ments. Delta-B box Cullin-1 (dominant-negative
Cullin-1 (1–456)) plasmid was a kindly gift from Dr.
Zhen-Qiang Pan (Derald H. Ruttenberg Cancer Center,
New York) [22]; delet-F-box-Skp2-V5 was a kindly gift
from Dr. Thilo Hagen (National University of Singapore)
[23]. All the siRNAs, including siSkp1, siCSN5, siUbc12,
and siCdh1, were from Qiagene (Valencia, CA). All the
transient transfections were performed using Lipofecta-
min 2000 from Invitrogen.
Promoter activity and luciferase assay
PC3 cells were co-transfected with Skp2-Luc and Renilla
luciferase plasmid pGL 4.71 (Promega) by Lipofectamine
2000 (Invitrogen). After 48 h of transfection, FKB was
added as indicated with triple replications. Then cells
were harvested and luciferase activity was measured with
the Dual-Glo Luiferase assay system (Promega). Renilla
luminescence was used as an inner control for cell num-
bers and transfection efficiency. The relative ratio of lu-
minescence from interested gene promoter to Renilla
luminescence was shown in the figures as promoter
activity.
In vitro NEDD8 initiation conjugation assay
The NEDD8 initiation conjugation assay kit was pur-
chased from Bonston Biochem (Cambridge, MA). A
master mix of 0.4 μM APP-BP1/UBA3 (NEDD8 ligase
E1), 12.5 μM UbcH12 (NEDD8 ligase E2) and 62.5 μM
NEDD8 were prepared in the reaction buffer (pH 8.0, 50
mM HEPES and 50 mM NaCl in final reaction) and dis-
tributed to individual tubes with a volume of 15 μl. A
series of dilutions of FKB were made in DMSO. One
microliter of FKB or DMSO were added to the indicated
tubes and mixed well. The reactions were started by
adding 2.5 mMMg2+ and 1mM ATP (4 μl in mixture),
except the negative control tube was added by equal vol-
ume of ddH2O. The reaction tubes were incubated in
37 °C for 30 min and stopped by adding 5 μl 25 mM
EDTA. Non-reducing western blot was performed with
anti-UbcH12 antibody to detect both Ubc12 bands and
Nedd8 conjugated Ubc12 bands.
Cellular thermal shift assay [24]
PC3 cells were washed in 1X PBS before splitting evenly
at 1 × 106 cells into 2-mL centrifuge tube in complete
medium. One of the 2-mL centrifuge tubes were treated
with 0.1% DMSO, while others were treated with indi-
cated concentrations of FKB. After 2 h incubation at 37 °C
in a water bath, the cells were washed and suspended in
600 μL of 1X cold PBS that containing protease inhibitor.
Each of the treated cells were split evenly into nine new
2-mL centrifuge tubes, labeled with temperature ranging
from 40 to 62 °C in increments of 3 degrees. The cells
were incubated for 3 min at the indicated temperature,
followed by 3min incubation at room temperature before
snap-frozen in liquid nitrogen. The cells were then lysed
via snap-frozen in liquid nitrogen, thawing at 25 °C, and
brief vortexing three times, before being spun down at
13,000 rpm for 15min at 4 °C. Prior to heating at 75 °C for
10min, 40 μL of the supernatants were mixed with 10 μL
5X loading dye containing β-mercaptoethanol, and then
used for Western Blot analysis. Primary antibodies against
the protein of interest were used.
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Cellular isothermal dose response assay [24]
Similarly to the CESTA experiment, PC3 cells were
washed in 1X PBS and split evenly at 1 × 106 cells into
eight 2-mL centrifuge tubes. The eight sets of 2-mL cen-
trifuge tubes were treated with increasing concentrations
of FKB as shown in the Figure legend, leaving one 2-mL
centrifuge tube with 0.1% DMSO as a vehicle control.
After 2 h of incubation at 37 °C, the cells were washed
with 1X PBS and suspended in 40 μL of PBS containing
protease inhibitor. The cells were incubated at an appro-
priate temperature for 3 min and left at room
temperature for 3 min before snap frozen in liquid nitro-
gen. Cells were lysed and Western blotting analysis was
performed as described in the CESTA method.
Statistical analysis
Comparisons of cell viabilities, fold change in levels of
mRNA, caspase activities and ubiquitination and protein
levels between different treatments were conducted
using Student’s t-test. All statistical tests were two sided.
P < 0.05 was considered statistically significant.
Results
FKB inhibits Cullin-1 and Ubc12 neddylation
We have identified that FKB is the most potent apop-
tosis inducer of chalcones isolated from kava root ex-
tracts for inhibition of the growth of prostate cancer cell
lines with minimal effects on normal prostate epithelial
cells [13]. A further screening assay suggested that FKB
may function as a neddylation inhibitor (data not
shown). We therefore examined the expression of
NEDD8 and its modified proteins in PC3 cells after FKB
treatment. FKB treatment decreased neddylation of mul-
tiple proteins, including Cullins, NAE1, UBA3, etc. in
both a dose- and time- dependent manner (Fig. 1a).
Western blotting analysis confirmed that FKB reduced
A B
C D
Fig. 1 FKB inhibits the neddylation of Cullin1 and Ubc12. a, PC3 cells were treated with indicated concentrations of FKB for different periods of
time. Expression of NEDD8 and its modified proteins were measured by Western blotting analysis. b, Western blotting analysis of Cullin1
neddylation in vehicle control (0.1% DMSO) or 8.8 μM FKB treated LNCaP and PC3 cells. c, Cullin1 neddylation was measured via
immunoprecipitation with anti-Cullin1 and then Western blotting analysis of the immunoprecipitates by anti-NEDD8 antibody in vehicle control
or 8.8 μM FKB treated DU145 and PC3 cells. d, PC3 cells were treated with 8.8 μM FKB or 1 μM MLN4924 for 16 h. Neddylation of Cullin1 and
Ubc12 and expression of ubiquitinated proteins and Skp2 were examined by specific antibodies and β-tubulin serves as a loading control
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Cullin-1 neddylation in LNCaP and PC3 cells (Fig. 1b).
In addition, immunoprecipitation experiments were con-
ducted by using anti-Cullin-1 antibody to pull down its as-
sociated complexes and detecting the pull down Cullin-1
with an anti-NEDD8 antibody. The result demonstrates
that the level of NEDD8-modified Cullin-1 decreases in
both DU145 and PC3 cells when treated with FKB (Fig.
1c). In addition, we used a reported neddylation inhibitor,
MLN4924, as a positive control for deneddylation [6–10].
Though the effect of FKB on de-neddylation was weaker
than MLN4924, FKB treatment resulted in an increased
ubiquitination of proteins accompanied by Skp2
down-regulation, whereas MLN4924 neither increase the
expression of ubiquitinated proteins nor decrease Skp2
expression (Fig. 1d). This result suggests that FKB is a
novel neddylation inhibitor with a different mechanism
from the known neddylation inhibitor MLN4924.
FKB interacts with NAE1 regulatory subunit to inhibit
UBC12 neddylation
Computational model was used to determine the potential
binding sites of FKB to NAE1, Ubc12, and Cullin1. NAE1
had the highest predicted inhibition constant of approxi-
mately 986 nM by FKB (Fig. 2a), while best predicted in-
hibitory constant for Ubc12 and Cullin1 were 6.56 μM
and 7.07 μM of FKB (Data not shown), respectively. In
order to verify the direct effect of FKB on neddylation, an
in vitro neddylation initiation experiment was performed
where FKB was added to the reaction system of neddyla-
tion enzymes in a dose-dependent reaction. The inhibition
of Ubc12 neddylation was shown by non-denaturing
Western blotting analysis, and an increasing dose of FKB
was able to inhibit neddylation to Ubc12 (Fig. 2b, top).
The relative density of NEDD8-Ubc12 to the control was
analyzed to have an estimated IC50 of approximately11μM
(Fig. 2b, bottom). These results suggest that FKB inhibits
neddylation by hindering NAE1 activities.
CETSA was also performed to determine the direct
interaction between FKB and NAE1. Of the NAE1 com-
plex, the regulatory subunit, APP-BP1, was found to be
significantly shielded from degradation at an optimal
temperature of 58 °C (Fig. 2c) when co-incubated with
FKB at the optimal peak concentration of 8 .8μM (Fig.
2d), strongly suggesting that FKB directly binds to the
regulatory subunit.
FKB accelerates Skp2 degradation
Next, we have examined the effect of FKA on the
down-stream events of the neddylation pathway, such as
expression of an E3 ligase. FKB was shown to have a
dramatically downregulating effect on Skp2 protein
levels at a concentration of 8.8 μM in both androgen
receptor-positive C4-2B and androgen receptor negative
PC3 cells (Fig. 3a). Subsequently, the protein expression
of p27/Kip1, the major target substrate of Skp2, was also
shown to be increased (Fig. 3a). We then determine the
effects of FKB on Skp2 expression under
androgen-stimulated and androgen-deprived conditions.
Androgen deprivation reduces the protein expression of
Skp2 and addition of synthetic androgen into androgen
deprived media restores the expression of Skp2 in
LNCaP cells. When we treated LNCaP cells in presence
or absence of androgen and with FKB together, we found
Skp2 was decreased by FKB, regardless of if there were a
presence or absence of androgen (Fig. 3b). We next de-
termined whether FKB can affect Skp2 mRNA expres-
sion levels and Skp2 promoter activities. Unlike
proteasome inhibitors MG132 and Bortezomib, we
found that FKB had no significant effect on either Skp2
mRNA expression or the transcriptional activity of the
Skp2 promoter (Fig. 3c). These results indicate that the
decrease of Skp2 was likely due to the reduced protein
stability of Skp2 protein. We therefore employed cyclo-
heximide to block de novo protein synthesis and re-
corded the degradation rate of Skp2 in a time course
treatment of PC3 cells. We analyzed the Skp2 protein
expression levels over time and found that the rate of
Skp2 degradation is significantly increased under FKB
treatment (Fig. 3d).
FKB increases Skp2 ubiquitination leading to its
degradation
To evaluate whether the Skp2 degradation by FKB de-
pends on the proteasome function, PC3 cells with or
without ectopic expression of Skp2 were treated with
FKB, proteasome inhibitor MG132 alone or their com-
bination. Figure 4a shows that FKB and MG132 combin-
ation resulted in enhanced down-regulation of
endogenous Skp2 compared to either alone, whereas the
degradation of ectopically expressed Skp2 protein (which
is driven by the CMV promoter but not endogenous
transcriptional factors) by FKB was completely blocked
by MG132. This result indicates that the FKB induced
Skp2 degradation relies on intact proteasome function.
Figure 4b have further demonstrated that FKB has no ef-
fect on the proteasome function at its concentrations for
inducing Skp2 degradation when compared to MG132.
In addition, we have observed that the ubiquitinated
Skp2 level was increased under FKB treatment in both
Skp2 and ubiquitin immunoprecipitation assays (Fig. 4c
left and middle panel), and the whole ubiquitination level
in cell lysate was also increased marginally (Fig. 4c
right panel). A quantitative analysis of ubiquitination
level of Skp2 also demonstrated a significant increase
in ubiquitin modified Skp2 when treated with FKB
(Fig. 4d). Together, these results demonstrate that
FKB decreases Skp2 by increasing its ubiquitination,
which can be recognized and degraded by proteasome
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and its degradation in the proteasome without affect-
ing the proteasome function itself.
FKB induced Skp2 degradation is dependent on a
functional Cullin-1
There are at least two reported mechanisms involved in
Skp2 ubiquitination and degradation [19]. One is that
Skp2 is ubiquitinated by another E3 ligase complex, such
as the APC/C complex with Cdh1, the other one being
the Skp1-Cullin-1-ROC/Rbx1 complex which is referred
to as self-ubiquitination of Skp2. We first knocked down
Cdh1 by siRNA and found that FKB-induced Skp2 de-
crease is not restored in the Cdh1 knock down
conditions and that Cdh1 knockdown led to increased
protein expression of Skp2 (Fig. 5a). This result suggests
that FKB induced Skp2 degradation is not dependent on
the expression of Cdh1.
We therefore turned our investigation into the
Cullin-1, which is post-transcriptionally modified by
neddylation and serve as a bridge to link ROC/Rbx1/
ubiquitin-conjugating enzyme E2 to the Skp1/Skp2 com-
plex for ubiquitin transfer. A full-length wild-type Cul-
lin1 expression plasmid, a dominant negative Cullin-1
expression plasmid that retains the binding to the Skp1/
Skp2 complex but lacks the E2 (i.e. ROC/Rbx1) binding
domain, or a mutant Cullin-1(K720R) with disruption of
A B
C D
Fig. 2 FKB interacts with the NAE1 to inhibit Ubc12 neddylaton. a, Autodocktools program was used to dock FKB with the NAE1 protein (3gzn),
which has a predicted IC50 of 986.1 nM, and Pymol program was used to observe the superimposed binding of FKB to NAE1. FKB was predicted
to bind within the E1 regulatory subunit (grey) of NAE1. b, In vitro Ubc12 neddylation initiation assay was performed. Ubc12 antibody was used
to detect the changes of NEDD8- conjugated Ubc12 bands, which are inhibited by FKB treatments. Densitometry analysis of Western blotting
bands shows an estimated IC50 of ~ 11 μM for FKB to inhibit Ubc12 neddylation. c, Cellular thermal shift assay was performed using PC3 cells
treated with 8.8 μM FKB or 0.1% DMSO under a range of temperatures from 40cC to 62 °C. Western blotting bands were semi-quantified by
densitometry analysis and adjusted by loading control β-tubulin. The line graph shows relative changes of density ratios from 40cC to 62 °C. Error
bars represent standard deviations of three replicates. d. Cellular isothermal dose response was examined on PC3 cells at 58 °C and treated with
FKB at concentrations ranged from 0.3125 μM to 20 μM, where 0.1% DMSO was used as a vehicle control. The line graph shows relative changes
of density ratios from different concentrations of FKB treatment relative to vehicle control. CT denotes control. Error bars represent standard
deviations of three replicates
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the NEDD8 conjugation site expression plasmid as
shown in Fig. 5b was then transfected into 293 T cells.
After transfection, these transfected cells were treated
with 8.8 μM FKB for 24 h. Western-blot analysis shows
that FKB induced Skp2 degradation was fully blocked
when Cullin1 activities were hindered by expression of
dominant-negative or neddylation site deleted Cullin-1
(Fig. 5c). The expression of F-box-deleted Skp2 protein
that losses its binding to the Cullin-1 complex via Skp1
also cannot be decreased by FKB treatment (Fig. 5d). As
suggested by these results, a functional Cullin1 that acts
as a bridge for transferring ubiquitin from E2 to E3 lig-
ase may be required for FKB induced Skp2 degradation.
Furthermore, NEDD8 is removed from cullins by spe-
cific isopeptidase activity of the COP9/signalosome (CSN)
complex, including CSN5 [25]. siRNA knockdown of
CSN5, Ubc12, or Skp1 in PC3 cells decrease the expres-
sion of Skp2 and is not able to rescue the effect of FKB in-
duced Skp2 degradation. These results suggest that FKB
induced Skp2 degradation doesn’t require the expression
of CSN5, Ubc12 and Skp1 (Additional file 1: Figure S1).
FKB enhances the anti-cancer effects of proteasome
inhibitors via Skp2 down-regulation
We have shown that proteasome inhibitors (MG132 and
Bortezomib) inhibit the mRNA expression and promoter
A
C
B
D
Fig. 3 FKB downregulates Skp2 expression via protein degradation. a, Western blotting analysis of protein expression of Skp2 and p27/Kip1 in
PC3 and C4-2B cells that were treated with vehicle control (0.1% DMSO) or indicated concentrations of FKB for 24 h. β-tubulin was used as a
loading control. b, LNCaP cells were cultured under 10% charcoal stripped FBS with or without 10 nM synthetic androgen R1881 and then
treated with vehicle control (0.1% DMSO) or 8.8 μM FKB for 24 h. The protein expression of Skp2 was decreased by FKB treatment. c, PC3 cells
were treated with 0.5% DMSO, 8.8 μM FKB, 5 μM MG132 or 10 nM Bortezomib for 16 h. Real-time RT-PCR was performed to analyze mRNA
expression of Skp2. PC3 cells were co-transfected with Skp2-Luc along with a Renilla luciferase plasmid pGL 4.71 and Luciferase activities were
measured. Proteasome inhibitors MG132 and Bortezomib but not FKB significantly decrease mRNA expression and promoter activity of Skp2
(Student t test, Ps < 0.05). Bars are mean ± SD of three independent experiments. d, PC3 cells were treated with 10 μg/L of cycloheximide (CHX).
After 16 h of treatment, the cells were treated in absence or presence of 8.8 μM of FKB. Western blotting was performed to determine Skp2
protein levels and quantified by densitometry with Image J software and adjusted for loading control. FKB reduces Skp2 protein stabilities
over time
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activity of Skp2 in PC3 cells, indicating a mechanism
through transcriptional down-regulation of Skp2 (Fig. 3c).
Consistently, proteasome inhibitors (MG132 and Bortezo-
mib) had more potent effect on reducing cell viabilities of
Skp2 overexpressing PC3/Skp2 cells than PC3/PcDNA
cells with less Skp2 expression, which suggests that Skp2
is a potential target for the growth inhibitory effect of
these proteasome inhibitors (Additional file 1: Figure S2).
The IC50s of MG132 and Bortezomib for PC3/Skp2 cells
were estimated to be approximately 252.2 ± 34.1nM and
14. 1 ± 1. 7 nM, respectively, compared to 832.7 ± 45.7nM
and more than 20 nM for PC3/PcDNA cells (Ps < 0.05).
Since FKB targets Skp2 degradation for its growth in-
hibitory effect on prostate cancer cell lines (Fig. 3 and
Additional file 1: Figure S3), we examined whether the
anti-prostate cancer effects of MG132 or Bortezomib
could be enhanced via combination with FKB. Figure 6a
shows that MG132, Bortezomib or FKB alone at
concentrations minimally to slightly inhibit the growth
of prostate cancer cell lines (i.e. C4-2B, DU145 and
PC3), whereas their combinations results in approxi-
mately 30 to 84% growth inhibition on these cell lines,
respectively, suggesting an additive to synergistic ef-
fect dependent on cell lines. Western blotting analysis
further demonstrates that MG132, Bortezomib or FKB
either alone decreases the protein expression of Skp2
by less than 50%, and that their combinations results
in a complete inhibition of Skp2 protein expression
(Fig. 6b and Additional file 1: Figure S4). Further-
more, combination of FKB with MG132 lead to mark-
edly enhanced expression of cell cycle inhibitors p27/
Kip1 and p21/WAF1 (Fig. 6b). Furthermore, combin-
ation of FKB and MG132 causes an increased cleav-
age of PARP and Caspase 3/7 compared to each
treatment alone (Fig. 6c), indicating an enhanced
apoptosis by the combination.
A
C
B
D
Fig. 4 FKB degrades Skp2 protein in a proteasome and ubiquitination dependent manner. a, Western blotting analysis of Myc-Skp2 and
endogenous Skp2 protein expression after PC3/Skp2 or PC3/PCDNA cells were treated with FKB, MG132 or their combination for 24 h. b,
proteasome activities (i.e. OD values) were measured by the 20S Proteasome Assay Kit after PC3 cells were treated with 0.1% DMSO, FKB or
MG132 for 24 h. c, Skp2 ubiquitination was measured by immunoprecipitation with anti-ubiquitin antibody and then Western blotting analysis of
immunoprecipitates by anti-Skp2 after PC3 cells were treated with 0.1% DMSO or FKB (left two panels). 293 cells were transiently transfected with
Skp2 and ubiquitin expression plasmids. After 24 h of transfection, cells were treated with 0.1% DMSO or FKB for 16 h. FKB increases
ubiquitination of Skp2. d, the relative ubiquitination levels were measured by the Ubiquitylation Assay Kit after DU145 cells were treated by 0.1%
DMSO, 8.8 μM FKB, 5 μM MG132 for 16 h
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Defects in the RB1 tumour suppressor are one of the
more common driver alterations in prostate cancer pro-
gression [26–31] and Skp2 was shown to be required for
RB1 loss initiated pituitary tumorigenesis [32]. Here, we
observed that the mRNA levels of Skp2 in RB1 knockout
mouse embryonic fibroblasts (MEFs) are approximately
8 fold higher than those in wild-type MEFs (Fig. 7a). In
addition, we demonstrate that FKB selectively inhibits
the growth of RB1 deficient cells: The IC50s of RB−/−
MEFs and mouse prostate epithelial cells (MPECs) were
estimated to be approximately 12 μM and 10 μM com-
pared to IC50s of their wild type control counterparts
25 μM and 31 μM, respectively (Fig. 7b and c, Ps < 0.05).
Our results can be simply summarized as Fig. 6d,
which indicates that the combination of suppressing
Skp2 transcription by proteasome inhibitors and indu-
cing Skp2 protein degradation via FKB may cause
synergistic downregulation Skp2 expression leading to
pronounced up-regulation of p27/Kip1 andp21/WAFs,
activation of caspase cascade, cell growth inhibition
and apoptosis. RB deficient prostate cancer may be
particularly sensitive to the FKB and Bortezomib
combination therapy.
Discussion
The results from our experiment support the hypothesis
that FKB’s inhibitory effect on prostate cancer cells is
due to FKB’s binding to the NAE1 regulatory subunit
APP-BP1. Our CETSA results confirm that FKB directly
binds to APP-BP1, which in turn was our prediction
based on molecular docking. This binding results in two
distinct events. The first is that FKB treatment prevents
neddylation of Cullin-1 and Ubc12. The second distinct
event is that treatment with FKB simultaneously causes
a downstream ubiquitination and degradation of E3 li-
gases SKP2. These observations suggest that FKB is dis-
tinct from a known neddylation inhibitor MLN4924,
which forms NEDD8-MLN4924 adduct to inhibit neddy-
lation of Cullin-1 and Ubc12 [5–10] but didn’t induce
protein ubiquitination and Skp2 degradation.
A B
C
D
Fig. 5 Degradation of Skp2 by FKB is dependent on Cullin1 activity. a, PC3 cells were transiently transfected with siRNA control or Cdh1siRNAs.
The knockdown effects on Skp2 expression were evaluated by Western blotting analysis. FKB decreases Skp2 expression under Cdh1 knockdown
conditions. b, cartoon depiction of ubiquitin transfer from E2 to E3 substrate in the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex. c,
left panel: PC3 cells stably expressing dominant-negative (DN) Cullin1 or vector control (PcDNA3), middle panel: 293 T cells were transiently
transfected with mutant Cullin-1 (K720R) or PcDNA3, and right panel: 293 T cells were transiently transfected with full-length Cullin1 (1–728). Cells
were treated with 0.1%DMSO or 8.8 μM FKB for 24 h. Skp2 and p27/Kip1 expression was examined by Western blotting analysis. d, PC3 cells were
transfected with F-box deleted Skp2 (V5-del-F-box-Skp2). After 24 h of transfections, cells were treated with 0.1%DMSO or 8.8 μM FKB for 24 h,
and Skp2/V5 expression was examined by Western blotting analysis
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In addition, FKB demonstrates two characteristics
that make FKB or its derivatives valuable for further
investigation of its usefulness in combination therapy
for prostate cancer. The first one is that FKB select-
ively inhibits the growth of RB deficient cells by deg-
radation of Skp2. RB-deficient prostate tumors
present a significant clinical challenge [26–31]. Loss
of RB function was found with high frequency in
castration-resistant prostate cancer [26–31]. In one
way, most RB defective prostate tumors are associated
with high androgen receptor expression, poor progno-
sis, and resistance to hormone therapy [29, 30]. Clin-
ically, prostate cancer patients with early loss of RB
function were often found to be those men whose ab-
solute PSA value does not go down below 0.2 ng/ml
after androgen depletion [29, 30]. In the other way,
prostate cancer small cell/neuroendocrine phenotype,
an increasingly prevalent histologic subtype in castra-
tion resistant prostate cancer with low androgen re-
ceptor activity is also characterized by loss of RB
expression [31]. Our previous studies have demon-
strated that FKB is more potent in reducing cell via-
bilities of androgen receptor negative, castration
resistant prostate cancer cell lines [13], and that FKB
transcriptionally down-regulates the expression of an-
drogen receptor and its target genes leading to
A
B
C
D
Fig. 6 The combined effects of FKB and proteasome inhibitors MG132 and Bortezomib on cell viabilities, apoptosis and expression of Skp2 and
p27/Kip1. a, C4-2B, DU145 and PC3 cells were treated with 0.1%DMSO, 8.8 μM FKB, 5 μM MG132, 5 nM Bortezomib or their combinations for 24 h.
MTT assay was performed to measure cell viabilities. Bars are mean ± SD of three independent experiments. “*” denotes P < 0.05 and “**” denotes
P < 0.01. b, left panels: protein expression of Skp2, p27/Kip1, p21/WAF1, and cleaved PARP was measured after DU145 cells were treated with
0.01% DMSO, 8.8 μM FKB, 5 μM MG132), or their combinations for 24 h. Right panels: DU145 and PC3 cells were treated with 8.8 μM FKB, 20 μM
flavokawain A (FKA), 5 nM Bortezomib, or their combinations. Skp2 protein levels were examined. c, the caspase 3/7 activities were measured by
ELISA kit after DU145 cells were treated with 0.1% DMSO, 8.8 μM FKB, 5 μM MG132, and their combination for 24 h. Bars are mean ± SD of three
independent experiments. d, schematic presentation of mechanisms for the combined effects of FKB and proteasome inhibitors. FKB degrades
Skp2 via inhibition of Ubc12/Cullin1 neddylation, whereas proteasome inhibitors down-regulation of Skp2 expression through transcriptional
suppression. The combination results in enhanced up-regulation of p21/WAF1, p27/Kip1, and cleaved PARP, leading to greater growth inhibition
and apoptosis
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inhibition of in vivo tumor growth in patient derived
xenograft models [12]. Skp2 expression has been
shown to be required for RB loss initiated pituitary
tumorigenesis in mouse models [32]. More recently,
multiple components of the SCFSKPCullin F box con-
taining complex including Skp2 has been identified to
be candidates of highly penetrant, synthetic lethal in-
teractions in RB defective triple negative breast cancer
[33]. Taken together, these results provide a strong
rationale that targeting Skp2 by FKB, its derivatives,
or proteasome inhibitors (i.e. Bortezomib) should be
evaluated as a novel approach for treatment of RB
defective, castration resistant prostate cancer.
While FKB is not as potent as MLN4294 for inhibition
of neddylation, the second characteristic of FKB is that
when combined with the proteasome inhibitors Bortezo-
mib or MG132, the anti-prostate cancer effects were sig-
nificantly enhanced. The combination of Bortezomib
with FKB for enhanced anti-prostate cancer effects is
also mechanistically or rationally justified, given that
Bortezomib and FKB act through two distinct mecha-
nisms for down-regulation of Skp2 expression: one is
through suppression of transcription and the other is
through protein ubiquitination and degradation. Further-
more, inhibition of Skp2 has been shown to overcome
the resistance to Bortezomib in multiple myeloma [20].
Conclusion
In conclusion, FKB is a new inhibitor of protein ned-
dylaiton, which is mechanistically distinct from
MLN4924 (Pevonedistat), a known neddylation inhibi-
tor currently on clinical trials for treatment of cancers
[5–10]. FKB directly interacts with the NAE1 regula-
tory subunit APP-BP1, resulting in deneddylation of
Ubc12 and Cullin1, reduced activity of the SCFSKP2
complex and SKP2 ubiquitination and degradation, as
well as up-regulation of p21/WAF1 and p27/Kip1and
activation of the caspase mediated apoptotic pathway.
When combined with Bortezomib, the growth inhibi-
tory effect was increased than either alone, indicating
A
B C
Fig. 7 FKB selectively inhibits the growth of RB deficient cells compared to RB wild type cells. a, mRNA expression of Rb and Skp2 was analyzed
via RT-PCR and qPCR in MEF wild-type and Rb−/− cell lines. b, Mouse embryonic fibroblasts (MEFs) and c, mouse prostate epithelial cells (MPECs),
wild-type and Rb−/−, were treated with 0.1% DMSO or indicated concentration of FKB for 72 h. Cell viabilities were measured via MTT assays
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FKB as a promising candidate for drug combination
therapy of prostate cancer. Further research will be
directed at the synthetic lethal interaction of RB loss
with Skp2 overexpression in castration-resistant pros-
tate cancer and targeting of Skp2 by combination of
Bortezomib and FKB or its derivatives for treatment
of RB deficient, castration resistant prostate cancer.
Additional file
Additional file 1: Supplmentary Figures S1-S4. (PPTX 392 kb)
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